- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Melinda Magyari Discusses Data on Treating Pediatric MS
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).
Transcript
How good is our current body of data on treating pediatric MS?
Because there have not been randomized control trials, only a few of them in pediatric-onset MS, the current evidence is not very strong. Randomized controlled trials exclude patients younger than 18 years. So I would, and as you can see in my presentation, most of the patients have been treated with intramuscular interferons. So the body of evidence on that treatment is rather good. But we need more observational data. We need large cohorts, maybe to merge them. Because the data is there, we just have to provide evidence.
